What Next In Oncology?

Finding The Next Generation Of Cancer Mega-Blockbusters Is Challenging

Oncology dominates pharma sales and pipeline league tables. But where is the next Keytruda? 

Question mark
• Source: Shutterstock

Cancer treatment has transformed over the last 25 years. Since the first genetically targeted treatments emerged in the 1990s and immune checkpoint inhibitors in the 2010s, oncology has consistently overshadowed other therapy areas. Cancer tops the approved drugs roster, the number and combined value of R&D programs, dealmaking numbers and venture capital investment. Total cancer drug sales of $180bn in 2022 eclipsed other areas and will grow to over $340bn by 2028, according to Evaluate. That’s more than double the next-best placed category, neurology products.

But the two most valuable cancer drugs, Merck & Co., Inc.’s Keytruda (pembrolizumab) and Johnson & Johnson’s anti-CD38...

Read the full article – start your free trial today!

Join thousands of industry professionals who rely on In Vivo for daily insights

  • Start your 7-day free trial
  • Explore trusted news, analysis, and insights
  • Access comprehensive global coverage
  • Enjoy instant access – no credit card required

More from Innovation

Infographic: How Big Pharma Is Scaling Beyond Pilot AI Projects

 
• By 

Pharma leaders are shifting from AI pilots to enterprise-scale deployment, favoring external partnerships for efficiency gains while maintaining tight control over sensitive clinical data.

IMMA Starts A Silent Revolution By Making IVF Journey Digital, Predictable And At Home

 
• By 

IMMA’s transvaginal at-home ovarian stimulation monitoring system using ultrasound and AI image analysis increases the chances of early IVF success. It won the Biomed Israel 2025 IVD start-up showcase award. Further potential applications could follow, cofounder/CEO Beatrice Chemla told In Vivo.

CRL Trio Brings Shifting Sand To Regenerative Medicine Regulation

 

Replimune's RP1 oncolytic immunotherapy became the third regenerative medicine to receive an FDA complete response letter this month as the agency appears to re-visit previous agreements about accelerated approval.

When Simple Is Best: A Pre-Term Birth Device To End The ‘Silent Emergency’

 
• By 

The Lioness non-surgical silicon ring implant is designed to put an end to pre-term births, sparing maternal anguish and saving health system costs. PregnanTech won the Biomed Israel 2025 medtech start-up award, and Limor Sandach told In Vivo how a non-digital technology beat off stiff competition.

More from In Vivo

Q&A: Commercializing Oncology Products, Strategic Insights For Drug Developers

 
• By 

John Arena, president of Global Pharma Services at Cencora, talks to In Vivo about how companies can strategize market entry for oncology products.

Financing Quarterly Statistics, Q2 2025

 
• By 

During Q2, biopharmas brought in an aggregate $17.5bn in financing and device company fundraising totaled $2.7bn; while in vitro diagnostic firms and research tools players raised $1.7bn

IMMA Starts A Silent Revolution By Making IVF Journey Digital, Predictable And At Home

 
• By 

IMMA’s transvaginal at-home ovarian stimulation monitoring system using ultrasound and AI image analysis increases the chances of early IVF success. It won the Biomed Israel 2025 IVD start-up showcase award. Further potential applications could follow, cofounder/CEO Beatrice Chemla told In Vivo.